- Home
- EBF vs YMAB Comparison
EBF vs YMAB Comparison
Compare EBF & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBF
- YMAB
- Stock Information
- Founded
- EBF 1909
- YMAB 2015
- Country
- EBF United States
- YMAB United States
- Employees
- EBF N/A
- YMAB N/A
- Industry
- EBF Office Equipment/Supplies/Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EBF Consumer Discretionary
- YMAB Health Care
- Exchange
- EBF Nasdaq
- YMAB Nasdaq
- Market Cap
- EBF 613.0M
- YMAB 631.1M
- IPO Year
- EBF N/A
- YMAB 2018
- Fundamental
- Price
- EBF $20.75
- YMAB $10.10
- Analyst Decision
- EBF
- YMAB Strong Buy
- Analyst Count
- EBF 0
- YMAB 9
- Target Price
- EBF N/A
- YMAB $21.56
- AVG Volume (30 Days)
- EBF 139.5K
- YMAB 274.1K
- Earning Date
- EBF 12-16-2024
- YMAB 11-08-2024
- Dividend Yield
- EBF 16.78%
- YMAB N/A
- EPS Growth
- EBF N/A
- YMAB N/A
- EPS
- EBF 1.57
- YMAB N/A
- Revenue
- EBF $404,201,000.00
- YMAB $84,553,000.00
- Revenue This Year
- EBF N/A
- YMAB $10.24
- Revenue Next Year
- EBF N/A
- YMAB $20.21
- P/E Ratio
- EBF $13.17
- YMAB N/A
- Revenue Growth
- EBF N/A
- YMAB N/A
- 52 Week Low
- EBF $18.88
- YMAB $5.29
- 52 Week High
- EBF $25.75
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- EBF 40.22
- YMAB 21.95
- Support Level
- EBF $20.53
- YMAB $12.47
- Resistance Level
- EBF $20.77
- YMAB $11.11
- Average True Range (ATR)
- EBF 0.42
- YMAB 1.05
- MACD
- EBF 0.01
- YMAB -0.52
- Stochastic Oscillator
- EBF 28.04
- YMAB 4.04
About EBF Ennis Inc.
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialities, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360º Custom LabelsSM, ColorWorx, Enfusion, among others.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.